W. Rathmell
Last active: 10/30/2019

  1. Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients With Renal Medullary Carcinoma. Msaouel P, Hong AL, Mullen EA, Atkins MB, Walker CL, Lee CH, Carden MA, Genovese G, Linehan WM, Rao P, Merino MJ, Grodman H, Dome JS, Fernandez CV, Geller JI, Apolo AB, Daw NC, Hodges HC, Moxey-Mims M, Wei D, Bottaro DP, Staehler M, Karam JA, Rathmell WK, Tannir NM (2019) Clin Genitourin Cancer 17(1): 1-6
    › Primary publication · 30287223 (PubMed) · PMC6348017 (PubMed Central)
  2. Ultrasound Measurement of Vascular Density to Evaluate Response to Anti-Angiogenic Therapy in Renal Cell Carcinoma. Rojas JD, Papadopoulou V, Czernuszewicz TJ, Rajamahendiran RM, Chytil A, Chiang YC, Chong DC, Bautch VL, Rathmell WK, Aylward S, Gessner RC, Dayton PA (2019) IEEE Trans Biomed Eng 66(3): 873-880
    › Primary publication · 30059292 (PubMed) · PMC6691901 (PubMed Central)
  3. The Immune Landscape of Cancer. Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang TH, Porta-Pardo E, Gao GF, Plaisier CL, Eddy JA, Ziv E, Culhane AC, Paull EO, Sivakumar IKA, Gentles AJ, Malhotra R, Farshidfar F, Colaprico A, Parker JS, Mose LE, Vo NS, Liu J, Liu Y, Rader J, Dhankani V, Reynolds SM, Bowlby R, Califano A, Cherniack AD, Anastassiou D, Bedognetti D, Mokrab Y, Newman AM, Rao A, Chen K, Krasnitz A, Hu H, Malta TM, Noushmehr H, Pedamallu CS, Bullman S, Ojesina AI, Lamb A, Zhou W, Shen H, Choueiri TK, Weinstein JN, Guinney J, Saltz J, Holt RA, Rabkin CS, Cancer Genome Atlas Research Network, Lazar AJ, Serody JS, Demicco EG, Disis ML, Vincent BG, Shmulevich I (2019) Immunity 51(2): 411-412
    › Primary publication · 31433971 (PubMed)
  4. loss sensitizes cells to PI3Kβ and AKT inhibition. Terzo EA, Lim AR, Chytil A, Chiang YC, Farmer L, Gessner KH, Walker CL, Jansen VM, Rathmell WK (2019) Oncotarget 10(6): 647-659
    › Primary publication · 30774762 (PubMed) · PMC6363018 (PubMed Central)
  5. Individualised axitinib regimen for patients with metastatic renal cell carcinoma after treatment with checkpoint inhibitors: a multicentre, single-arm, phase 2 study. Ornstein MC, Pal SK, Wood LS, Tomer JM, Hobbs BP, Jia XS, Allman KD, Martin A, Olencki T, Davis NB, Gilligan TD, Mortazavi A, Rathmell WK, Garcia JA, Rini BI (2019) Lancet Oncol 20(10): 1386-1394
    › Primary publication · 31427205 (PubMed)
  6. Hypoxia, angiogenesis, and metabolism in the hereditary kidney cancers. Chappell JC, Payne LB, Rathmell WK (2019) J Clin Invest 129(2): 442-451
    › Primary publication · 30614813 (PubMed) · PMC6355237 (PubMed Central)
  7. Empowering ASCI's support of physician-scientists through stronger institutional connections. Marr KA, Rathmell WK, Hawley JB, Guth KD (2019) J Clin Invest 129(4): 1516-1518
    › Primary publication · 30932915 (PubMed) · PMC6436849 (PubMed Central)
  8. Von Hippel-Lindau mutations disrupt vascular patterning and maturation via Notch. Arreola A, Payne LB, Julian MH, de Cubas AA, Daniels AB, Taylor S, Zhao H, Darden J, Bautch VL, Rathmell WK, Chappell JC (2018) JCI Insight 3(4)
    › Primary publication · 29467323 (PubMed) · PMC5916240 (PubMed Central)
  9. VHL substrate transcription factor ZHX2 as an oncogenic driver in clear cell renal cell carcinoma. Zhang J, Wu T, Simon J, Takada M, Saito R, Fan C, Liu XD, Jonasch E, Xie L, Chen X, Yao X, Teh BT, Tan P, Zheng X, Li M, Lawrence C, Fan J, Geng J, Liu X, Hu L, Wang J, Liao C, Hong K, Zurlo G, Parker JS, Auman JT, Perou CM, Rathmell WK, Kim WY, Kirschner MW, Kaelin WG, Baldwin AS, Zhang Q (2018) Science 361(6399): 290-295
    › Primary publication · 30026228 (PubMed) · PMC6154478 (PubMed Central)
  10. Ultrasound Molecular Imaging of VEGFR-2 in Clear-Cell Renal Cell Carcinoma Tracks Disease Response to Antiangiogenic and Notch-Inhibition Therapy. Rojas JD, Lin F, Chiang YC, Chytil A, Chong DC, Bautch VL, Rathmell WK, Dayton PA (2018) Theranostics 8(1): 141-155
    › Primary publication · 29290798 (PubMed) · PMC5743465 (PubMed Central)